Stock Surge: Shares surge 50% in minutes, find out what happened to the company's stock.

News Topical, Digital Desk : Sometimes, news breaks in the stock market that can completely change a company's fortunes in a matter of minutes. This is exactly what happened with a telehealth company. Even before the market opened, the company's shares suddenly surged, rising by nearly 50 percent. Investors were left baffled as to what had happened. The real reason was a major settlement with a pharmaceutical company, ending a long-running legal dispute.

The situation changed within minutes.
Even before the market opened on Monday, investors were immediately drawn to the news that pharmaceutical giant Novo Nordisk had decided to withdraw its ongoing patent infringement lawsuit against Hims & Hers. As soon as this news broke, investors began buying Hims & Hers shares. As a result, the company's stock jumped by nearly 55 percent in pre-market trading. Later, the stock traded with a gain of approximately 43 percent.

It's common in the stock market that investor confidence increases upon news of a legal dispute ending or a major business deal. This is exactly what happened with Hims & Hers.

What was the controversy?
Some time ago, Hims & Hers planned to sell a pill that mimicked the popular weight-loss drug Wegovy. The company priced it at approximately $49, which was nearly $100 cheaper than the original.

This move angered pharmaceutical company Novo Nordisk. The company alleged that Hims & Hers was illegally compounding drugs on a large scale and violating patents.

The matter escalated to the point where the US drug regulatory agency, the FDA, became involved. The FDA warned of strict action against compounding pharmacies and stated that strict action would be taken for violations. After mounting pressure, Hims & Hers was forced to remove the copycat drug. The agreement has changed the entire equation . A new agreement has now been reached between the two companies. Under this agreement, Hims & Hers will sell Novo Nordisk's genuine branded drugs on its platform. These include injectable and oral semaglutide, known as Ozempic and Wegovy. The prices for these drugs will be the same as on other telehealth platforms. A key part of the agreement is that Hims & Hers will no longer heavily promote compounded GLP-1 drugs on its platform. According to Novo Nordisk CEO Mike Dustdar , the company's business model has changed . Hims & Hers has also agreed that compounded drugs will only be used in special cases. The company also says that patients previously taking compounded semaglutide can be switched to FDA-approved medications as needed. 

Read More: Stock market crash: 'Will the stock market fall by -10%? This is where investors' opportunity lies.'